-
1 Comment
SanBio Company Limited is currently in a long term downtrend where the price is trading 21.9% below its 200 day moving average.
From a valuation standpoint, the stock is 5930.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 4252.6.
SanBio Company Limited's total revenue sank by 0.0% to $23M since the same quarter in the previous year.
Its net income has increased by 12.9% to $-2B since the same quarter in the previous year.
Based on the above factors, SanBio Company Limited gets an overall score of 1/5.
Exchange | TSE |
---|---|
CurrencyCode | JPY |
ISIN | JP3336750009 |
Sector | Healthcare |
Industry | Biotechnology |
PE Ratio | None |
---|---|
Beta | -0.08 |
Market Cap | 194B |
Target Price | 1320 |
Dividend Yield | None |
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4592.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025